Mauna Kea Technologies SA Class O ALMKT

PARIS & BOSTON, July 21, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its sales for the first half of 2026.

PARIS & BOSTON, July 16, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.

PARIS & BOSTON, July 15, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (the "Company"), inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy platform (p/nCLE), today announces the establishment of a shareholder loan agreement with Vester Finance, repayable in cash or in new shares.

PARIS & BOSTON, June 04, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 4, 2026, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.

PARIS & BOSTON, June 03, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today highlighted the publication of a prospective study in the United European Gastroenterology Journal (Minea et al.1) that strengthens the case for Cellvizio as a differentiated tool to predict relapse in ulcerative colitis (UC). The study introduces "triple healing" as a new thera